AR107377A2 - Compuestos derivados de tetrahidroquinolina - Google Patents
Compuestos derivados de tetrahidroquinolinaInfo
- Publication number
- AR107377A2 AR107377A2 ARP170100115A ARP170100115A AR107377A2 AR 107377 A2 AR107377 A2 AR 107377A2 AR P170100115 A ARP170100115 A AR P170100115A AR P170100115 A ARP170100115 A AR P170100115A AR 107377 A2 AR107377 A2 AR 107377A2
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- heterocyclic
- sulfur
- oxygen
- Prior art date
Links
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 8
- 239000011593 sulfur Chemical group 0.000 abstract 8
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 239000001301 oxygen Substances 0.000 abstract 7
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- -1 oxyl group Chemical group 0.000 abstract 2
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000005156 substituted alkylene group Chemical group 0.000 abstract 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud divulga compuestos derivados de tetrahidroquinolina, o una sal farmacéuticamente aceptable del mismo que posee una actividad inhibitoria contra proteína de transferencia de colesteril éster (CETP). Reivindicación 1: Un compuesto caracterizado por que posee la fórmula (1), en donde R¹ es un átomo de hidrógeno, un grupo alcoxicarbonilo opcionalmente sustituido, un grupo carbamoilo opcionalmente sustituido, un grupo alquilo opcionalmente sustituido, un grupo alcanoilo opcionalmente sustituido, un grupo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de oxígeno, azufre y átomos de nitrógeno (el grupo heterocíclico es opcionalmente sustituido), o un grupo carbonilo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de oxígeno, azufre y nitrógeno (el grupo heterocíclico opcionalmente sustituido); R² es un átomo de hidrógeno o un grupo alquilo opcionalmente sustituido; R³ es un átomo de hidrógeno o un grupo alquilo opcionalmente sustituido; R⁴ es un grupo alquileno opcionalmente sustituido; R⁵ es un grupo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de oxígeno, azufre y nitrógeno, en donde el grupo heterocíclico es sustituido por 1 a 5 sustituyentes seleccionados de los grupos siguientes, o dicho grupo heterocíclico es sustituido por 1 a 5 sustituyentes seleccionados de grupos siguientes y además por un átomo halógeno, un grupo oxo y/o hidroxilo: grupo ciano, grupo nitro, grupo carboxilo, grupo sulfo, grupo alquilo C₃₋₁₀, grupo alquilo sustituido, grupo cicloalquilo opcionalmente sustituido, grupo alquenilo opcionalmente sustituido, grupo alcoxilo C₃₋₁₀, grupo alcoxilo sustituido, grupo cicloalcoxilo opcionalmente sustituido, grupo alcoxicarbonilo opcionalmente sustituido, grupo carbamoilo opcionalmente sustituido, grupo carbamimidoilo opcionalmente sustituido, grupo alquiltio opcionalmente sustituido, grupo alquilsulfinilo opcionalmente sustituido, grupo alquilsulfonilo opcionalmente sustituido, grupo amino opcionalmente sustituido, grupo sulfamoilo opcionalmente sustituido, grupo alcanoilo opcionalmente sustituido, grupo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de oxígeno, azufre y nitrógeno (el grupo heterocíclico es opcionalmente sustituido), un grupo oxilo monocíclico o heterocíclico bicíclico saturados o no saturado que contiene 1 a 4 heteroátomos seleccionados independientemente de átomos de oxígeno, azufre y nitrógeno (el grupo oxilo heterocíclico es opcionalmente sustituido), y un grupo carbonilo monocíclico o heterocíclico bicíclico saturado o no saturado que contiene 1 a 4 heteroátomos independientemente seleccionados de átomos de oxígeno, azufre y nitrógeno (el grupo carbonilo heterocíclico es opcionalmente sustituido); R⁶, R⁷, R⁸ y R⁹ son independientemente un átomo de hidrógeno, un átomo halógeno, un grupo hidroxilo, un grupo nitro, un grupo ciano, un grupo alquilo opcionalmente sustituido, un grupo alcoxilo opcionalmente sustituido, un grupo alquilsulfoniloxilo opcionalmente sustituido o un grupo amino opcionalmente sustituido; o R⁶ y R⁷, ó R⁷ y R⁸, ó R⁸ y R⁹ pueden combinarse en los extremos para formar un grupo alquileno cuyo grupo alquileno puede contener 1 a 3 heteroátomos independientemente seleccionados de los átomos de nitrógeno, azufre y oxígeno, y puede tener un sustituyente(s); y R¹⁰ es un anillo aromático que contiene opcionalmente 1 a 3 heteroátomos independientemente seleccionados de átomos de oxígeno, azufre y nitrógeno (el anillo aromático es opcionalmente sustituido); o una sal farmacéuticamente aceptable del mismo. Reivindicación 19: Un compuesto de la fórmula (2), caracterizado por que los símbolos R¹, R², R³, R⁵, R⁶, R⁷, R⁸ y R⁹ tienen el mismo significado como el definido en la reivindicación 1, o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004109550 | 2004-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107377A2 true AR107377A2 (es) | 2018-04-25 |
Family
ID=34963484
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101294A AR048361A1 (es) | 2004-04-02 | 2005-04-01 | Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos |
| ARP170100115A AR107377A2 (es) | 2004-04-02 | 2017-01-17 | Compuestos derivados de tetrahidroquinolina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101294A AR048361A1 (es) | 2004-04-02 | 2005-04-01 | Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7872126B2 (es) |
| EP (1) | EP1730152B1 (es) |
| JP (1) | JP4565077B2 (es) |
| KR (1) | KR100905684B1 (es) |
| CN (2) | CN101381345A (es) |
| AR (2) | AR048361A1 (es) |
| AT (1) | ATE556077T1 (es) |
| AU (1) | AU2005228290B2 (es) |
| BR (1) | BRPI0509364B8 (es) |
| CA (1) | CA2560402C (es) |
| DK (1) | DK1730152T3 (es) |
| EA (1) | EA011670B1 (es) |
| EC (1) | ECSP066967A (es) |
| ES (1) | ES2383900T3 (es) |
| IL (1) | IL178195A (es) |
| MX (1) | MXPA06011415A (es) |
| MY (1) | MY158055A (es) |
| NO (1) | NO20065011L (es) |
| NZ (1) | NZ550268A (es) |
| PL (1) | PL1730152T3 (es) |
| PT (1) | PT1730152E (es) |
| TW (1) | TWI338684B (es) |
| UA (1) | UA90269C2 (es) |
| WO (1) | WO2005095409A2 (es) |
| ZA (1) | ZA200608117B (es) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| MXPA06014716A (es) * | 2004-06-24 | 2007-03-12 | Lilly Co Eli | Compuestos y metodos para el tratamiento de dislipidemia. |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| WO2006073973A2 (en) | 2004-12-31 | 2006-07-13 | Reddy Us Therapeutics, Inc. | Novel benzylamine derivatives as cetp inhibitors |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| PT2248812E (pt) * | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
| US7582691B2 (en) * | 2007-01-17 | 2009-09-01 | Sabic Innovative Plastics Ip B.V. | Poly(arylene ether) compositions and articles |
| JP4834699B2 (ja) * | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AU2012202172B2 (en) * | 2007-11-05 | 2013-08-29 | Novartis Ag | 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| HRP20120476T1 (hr) * | 2007-11-05 | 2012-06-30 | Novartis Ag | Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza |
| EA017939B1 (ru) | 2007-12-03 | 2013-04-30 | Новартис Аг | Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз |
| EP2430018B1 (en) | 2009-05-15 | 2013-07-03 | Novartis AG | Benzoxazolone derivatives as aldosterone symthase inhibitors |
| SI2429995T1 (sl) | 2009-05-15 | 2014-05-30 | Novartis Ag | Arilpiridini kot inhibitorji aldosteron sintaze |
| MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| ES2551002T3 (es) | 2009-11-17 | 2015-11-13 | Novartis Ag | Derivados de aril-piridina como inhibidores de la aldosterona sintasa |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| ES2472446T3 (es) | 2009-11-30 | 2014-07-01 | Novartis Ag | Derivados de imidazol como inhibidores de aldosterona sintasa |
| WO2012005343A1 (ja) * | 2010-07-09 | 2012-01-12 | 第一三共株式会社 | 置換ピリジン化合物 |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| CA2845284C (en) | 2011-08-18 | 2018-03-06 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors |
| AU2012313971B2 (en) | 2011-09-27 | 2016-09-29 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis |
| US9321747B2 (en) | 2012-01-06 | 2016-04-26 | Daiichi Sankyo Company, Limited | Acid addition salt of substituted pyridine compound |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| PE20151666A1 (es) | 2013-02-14 | 2015-11-19 | Novartis Ag | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep |
| PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
| TW201536814A (zh) | 2013-07-25 | 2015-10-01 | Novartis Ag | 用於治療心臟衰竭之合成環狀多肽 |
| UA120922C2 (uk) | 2014-02-05 | 2020-03-10 | Дезима Фарма Б.В. | Інгібітор білка-переносника ефіру холестерину (cetp) і фармацевтичні композиції, які містять вказаний інгібітор, для застосування в лікуванні або запобіганні серцево-судинним захворюванням |
| KR102572626B1 (ko) * | 2014-08-12 | 2023-08-30 | 뉴암스테르담 파마 비.브이. | 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법 |
| CN112755032A (zh) * | 2014-08-28 | 2021-05-07 | 狄智玛制药私人有限公司 | 包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合 |
| CA2972871A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| WO2017023166A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor |
| WO2017023165A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| JP2024507810A (ja) * | 2021-02-18 | 2024-02-21 | ニューアムステルダム・ファルマ・ベー・フェー | 高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法 |
| DK4125911T3 (da) * | 2021-03-05 | 2024-07-15 | Newamsterdam Pharma B V | Obicetrapib til behandling af demens |
| CN113499860A (zh) * | 2021-07-08 | 2021-10-15 | 江西新金叶实业有限公司 | 一种铜再生回收冶炼渣高效浮选方法 |
| JP2024527023A (ja) | 2021-07-26 | 2024-07-19 | ニューアムステルダム・ファルマ・ベー・フェー | Ｈｉｓ低応答者の治療 |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| EP4456872A1 (en) | 2021-12-30 | 2024-11-06 | NewAmsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
| AU2023303916A1 (en) | 2022-07-05 | 2025-01-30 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| TW202416994A (zh) | 2022-08-22 | 2024-05-01 | 荷蘭商新阿姆斯特丹製藥公司 | 固定劑量醫藥組合物及其用途 |
| EP4661865A1 (en) | 2023-02-07 | 2025-12-17 | NewAmsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| KR20250172894A (ko) | 2023-04-24 | 2025-12-09 | 뉴암스테르담 파마 비.브이. | 비정질 오비세트라피브 및 sglt2 억제제 조합 |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
| CN116903544A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种奥比塞曲匹及其中间体的制备方法 |
| WO2025059594A1 (en) | 2023-09-15 | 2025-03-20 | Newamsterdam Pharma B.V. | METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) |
| WO2025093436A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146415A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| WO2025146445A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib and ezetimibe |
| WO2025147235A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Fixed dose combination composition of obicetrapib and ezetimibe |
| WO2025146446A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib |
| WO2025146262A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2760237B1 (fr) * | 1997-02-28 | 1999-04-16 | Rhone Poulenc Rorer Sa | Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant |
| FR2763590B1 (fr) * | 1997-05-22 | 2000-03-24 | Synthelabo | Derives d'acides[[[(arylmethyl)amino]carbonyl] alkyl]- aromatiques, leur preparation et leur application en therapeutique |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| JP2001348332A (ja) * | 2000-04-07 | 2001-12-18 | Takeda Chem Ind Ltd | 可溶性ベータ・アミロイド前駆蛋白質分泌促進剤 |
| JP2002053557A (ja) * | 2000-08-14 | 2002-02-19 | Japan Tobacco Inc | アポリポ蛋白ａ−ｉ産生促進薬 |
| NZ525614A (en) | 2000-12-18 | 2005-03-24 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| SE0101161D0 (sv) * | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
| US20030216398A1 (en) | 2001-04-05 | 2003-11-20 | Mitsuru Kakihana | Soluble beta amyloid precursor protein secretion promoters |
| RU2004123637A (ru) | 2002-02-01 | 2005-04-20 | Пфайзер Продактс Инк. (Us) | Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового |
| MXPA06014716A (es) | 2004-06-24 | 2007-03-12 | Lilly Co Eli | Compuestos y metodos para el tratamiento de dislipidemia. |
| JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
-
2005
- 2005-01-04 UA UAA200611525A patent/UA90269C2/ru unknown
- 2005-03-30 MY MYPI20051442A patent/MY158055A/en unknown
- 2005-03-30 TW TW094109940A patent/TWI338684B/zh not_active IP Right Cessation
- 2005-04-01 ES ES05728670T patent/ES2383900T3/es not_active Expired - Lifetime
- 2005-04-01 WO PCT/JP2005/006894 patent/WO2005095409A2/en not_active Ceased
- 2005-04-01 DK DK05728670.0T patent/DK1730152T3/da active
- 2005-04-01 CN CNA2008101454330A patent/CN101381345A/zh active Pending
- 2005-04-01 AU AU2005228290A patent/AU2005228290B2/en not_active Expired
- 2005-04-01 NZ NZ550268A patent/NZ550268A/en unknown
- 2005-04-01 CA CA2560402A patent/CA2560402C/en not_active Expired - Lifetime
- 2005-04-01 AR ARP050101294A patent/AR048361A1/es active IP Right Grant
- 2005-04-01 EA EA200601852A patent/EA011670B1/ru not_active IP Right Cessation
- 2005-04-01 CN CNB2005800103986A patent/CN100528878C/zh not_active Expired - Lifetime
- 2005-04-01 BR BRPI0509364A patent/BRPI0509364B8/pt active IP Right Grant
- 2005-04-01 KR KR1020067020435A patent/KR100905684B1/ko not_active Expired - Lifetime
- 2005-04-01 AT AT05728670T patent/ATE556077T1/de active
- 2005-04-01 PL PL05728670T patent/PL1730152T3/pl unknown
- 2005-04-01 MX MXPA06011415A patent/MXPA06011415A/es active IP Right Grant
- 2005-04-01 PT PT05728670T patent/PT1730152E/pt unknown
- 2005-04-01 JP JP2006534487A patent/JP4565077B2/ja not_active Expired - Lifetime
- 2005-04-01 EP EP05728670A patent/EP1730152B1/en not_active Expired - Lifetime
-
2006
- 2006-09-19 IL IL178195A patent/IL178195A/en active IP Right Grant
- 2006-09-27 US US11/527,691 patent/US7872126B2/en active Active
- 2006-09-29 ZA ZA200608117A patent/ZA200608117B/xx unknown
- 2006-10-31 EC EC2006006967A patent/ECSP066967A/es unknown
- 2006-11-01 NO NO20065011A patent/NO20065011L/no not_active Application Discontinuation
-
2010
- 2010-10-25 US US12/911,149 patent/US8158640B2/en active Active
-
2017
- 2017-01-17 AR ARP170100115A patent/AR107377A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107377A2 (es) | Compuestos derivados de tetrahidroquinolina | |
| AR059248A1 (es) | Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas | |
| AR059249A1 (es) | Compuesto amina trisustituido | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| PE20241625A1 (es) | Combinaciones farmaceuticas de inhibidores de sos1 para tratar o prevenir cancer | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
| EA201071078A1 (ru) | Новые производные карбазола, являющиеся ингибиторами hsp90, содержащие их композиции и их применение | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
| AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
| MX2010000658A (es) | Derivados de pirimidina 934. | |
| EA201190119A1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| EA200802052A1 (ru) | 2-(пиридин-2-ил)-пиримидины в качестве фунгицидов | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| PE20212327A1 (es) | Ciertos compuestos de pladienolida y metodos de uso | |
| EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
| PE20241934A1 (es) | Inhibidores de raf quinasa y metodos de uso de los mismos | |
| AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |